ZX008 meets Phase III goals in Dravet syndrome trial

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.

... read more at: https://www.thepharmaletter.com/article/zx008-meets-phase-iii-goals-in-dravet-syndrome-trial